DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the publication of a peer-reviewed manuscript titled "High- Efficiency Homology-Directed Insertion into the Genome using the Engineered Homing Endonuclease ARCUS†in the journal Nucleic Acids Research. This publication demonstrates a wide variety of g. ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the activation of its first U.S. clinical trial site to evaluate PBGENE-HBV as part of the ELIMINATE-B Phase 1 clinical trial. The newly activated site at Massachusetts General Hospital in Boston, Massachusetts, is now actively recruiting patients. ". ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society (WMS) being held October 7-12, 2025, in Vienna, Austria. "We look forward to sharing the latest preclinical data for PBGENE-DMD at the upcoming. ...

Core Insights - Precision BioSciences, Inc. is a clinical stage gene editing company focused on developing in vivo gene editing therapies for diseases with high unmet needs [1] - The company presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV targeting chronic Hepatitis B patients [1] - The presentation took place at the International Coalition to Eliminate HBV (ICE-HBV) "HBV Cure Symposium" in Berlin [1]